Toyama's novel flu antiviral moves into Phase III
This article was originally published in Scrip
Executive Summary
Toyama Chemical has begun a Phase III development programme in Japan for its novel antiviral agent favipiravir (T-705), which has shown promise against a broad range of flu types including H1N1 and H5N1.